


Express Mail Label: EL831676800US
Date of Deposit: August 23, 2001

Attorney Docket No. 19313-004 (NS-4)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

1651
RECEIVED

AUG 27 2001

TECH CENTER 1600/2900

APPLICANTS: Wahlberg, *et al.*

SERIAL NUMBER: 09/696,530

EXAMINER: Not Yet Assigned

FILING DATE: October 24, 2000

ART UNIT: 1651

FOR: CULTURES OF GFAP+ NESTIN+ CELLS THAT DIFFERENTIATE TO NEURONS

Box IDS

Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED
OCT 01 2001
TECH CENTER 1600/2900

TRANSMITTAL LETTER

Transmitted herewith for filing in the above-referenced patent application are the following documents:

- ☒ Information Disclosure Statement (2 pages), in duplicate;
- ☒ Modified Form 1449/PTO (3 pages), in duplicate;
- ☒ Copies of cited references A1-A13, B1-B12, and C1-C43; and
- ☒ Return postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at 617-542-6000, Boston, Massachusetts.


The Commissioner is authorized to charge any additional fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 19313-004 (NS-4). A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

Ivor R. Elrifi, Reg. No. 39,529
Cynthia A. Kozakiewicz, Reg. No. 42,764
Attorneys for Applicant
c/o MINTZ, LEVIN, COHN, FERRIS
GLOVSKY AND POPEO, P.C.
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

Date: August 23, 2001

Express Mail Label No.: EL831676800US
Date of Deposit: August 23, 2001



Attorney Docket No. 19313-004 (NS-4)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Wahlberg, *et al.*
ASSIGNEE: NSGene
SERIAL NO.: 09/696,530
FILING DATE: October 24, 2000
FOR: Cultures of GFAP+ NESTIN+ Cells That Differentiate to Neurons

Box IDS

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed below and on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application, copies of which are submitted herewith. The order of presentation of the references should not be construed as an indication of the importance of the references.

This Information Disclosure Statement is being been filed:

- ☐ within three months of the filing date of the National Application.
- ☐ within three months of the filing date of the entry of the National Stage, as set forth in 37 C.F.R. §1.491, in an International Application.
- ☒ before the mailing date of a first Office Action on the merits in the above-identified case.

Accordingly, no fee or certification is required. 37 C.F.R. §1.97.

A copy of each of the references is enclosed unless otherwise indicated on the attached Form PTO-1449 (modified). It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that

RECEIVED
AUG 27 2001
TECH CENTER 1600/2900
OCT 01 2001
TECH CENTER 1600/2900

the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested. Please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311 Reference No. 19313-004 (NS-4).

Respectfully submitted,




Ivor R. Elrifi, (Reg. No. 39,529)
Cynthia A. Kozakiewicz (Reg. No. 42,764)
Attorneys for Applicant
c/o MINTZ, LEVIN, COHN, FERRIS
GLOVSKY AND POPEO, P.C.
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

Dated: August 23, 2001

TRA 1552485v1

Express Mail No.: EL831676800US
Date of Deposit: August 23, 2001



Modified Form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application Number	09/696,530
Filing Date	October 24, 2000
First Named Inventor	Lars Wahlberg
Group Art Unit	1651 1647
Examiner Name	Not Yet Assigned <i>Stecher</i>
Attorney Docket Number	19313-004 (NS-4)

U.S. PATENT DOCUMENTS


Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A1	5,750,376	5/12/98	Weiss et al.			6/7/95
	A2	5,851,832	12/22/98	Weiss et al.			6/7/95
	A3	5,753,506	5/19/98	Johe			9/25/96
	A4	5,968,829	10/19/99	Carpenter			9/5/97
	A5	5,071,741	12/10/91	Brockbank			4/18/88
	A6	4,352,883	10/5/82	Lim			3/28/79
	A7	4,353,888	10/12/82	Sefton			12/23/80
	A8	5,084,350	1/28/92	Chang et al.			2/16/90
	A9	5,284,761	2/8/94	Aebischer et al.			2/26/92
	A10	5,158,881	10/27/92	Aebischer et al.			1/8/90
	A11	4,976,859	12/11/90	Wechs			9/1/89
	A12	4,968,733	11/6/90	Muller et al.			9/1/89
	A13	5,800,828	9/1/98	Dionne et al.			1/10/94

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes	No
	B1	WO 93/14191	Cryopharm Corporation	July 22, 1993		
	B2	WO 95/07611	Organogenesis Inc.	March 23, 1995		
	B3	WO 96/27287	Celox Laboratories, Inc.	Sept. 12, 1996		
	B4	WO 96/29862	Organ, Inc.	Oct. 3, 1996		
	B5	WO 98/14058	Regents of the University of California	Apr. 9, 1998		
	B6	WO 92/04033	The General Hospital Corp.	March 19, 1992		
	B7	WO 00/24897	Cytotherapeutics, Inc.	May 4, 2000		
	B8	WO 92/19195	Brown University Research Foundation	Nov. 12, 1992		
	B9	WO 95/05452	Cytotherapeutics, Inc.	Feb. 23, 1995		
	B10	WO 98/30678	Steindler, Dennis A.	July 16, 1998		
	B11	WO 96/04368	Dalhousie University	Feb. 15 1996		
	B12	WO 96/09543	Neurospheres LTD.	March 28, 1996		

OTHER NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1	Jessen et al., 13 Neurocytology 923-034 (1984)
	C2	Fields et al., 8 J. Neuroimmunol. 311-330 (1989)




OTHER NON PATENT LITERATURE DOCUMENTS

Exam No.	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C3	Lendahl et al., 60 Cell 585-595 (1990)
	C4	Gallo et al., 15 J. Neurosci 394-406 (1995)
	C5	Lin et al., 2 Neurobiol. Dis. 79-85 (1995)
	C6	Doetsch et al., 97 Cell 703-16 (1999)
	C7	Johansson et al., 96 Cell 25-34 (1999)
	C8	Lagenaur & Schachner, 15 J. Supramol. Struct Cell Biochem. 335-46 (1981)
	C9	Lagenaur et al., 23 J. Neurobiol. 71-88 (1992)
	C10	Zhou & Lund, 317 J. Comp. Neurol. 145-55 (1992)
	C11	Mi et al., 106 Dev. Brain Res. 145-54 (1998)
	C12	Hankin & Lund, 263 J. Comp. Neuro. 455-466 (1987)
	C13	Victorin et al., 3 Eur. J. Neurosci. 86-101 (1991)
	C14	Hunter et al., 33. J. Neurobiol. 459-472 (1997)
	C15	Mission et al., 44 Dev. Brain Res. 95-108 (1988)
	C16	Weiss et al., 19 Trends Neurosci. 387-93 (1996)
	C17	Reynolds et al., 12 J. Neurosci. 4565-74 (1992)
	C18	Reynolds & Weiss, 255 Science 1707-10 (1992)
	C19	Reynolds & Weiss, 175 Dev. Biol. 1-13 (1996)
	C20	Hammang et al., 147 Exp. Neurol. 84-95 (1997)
	C21	Svendsen et al., 148 Exp. Neurol. 135-46 (1997)
	C22	Vescovi et al., 156 Exp. Neurol. 71-83 (1999)
	C23	Karlsson et al., 65 Biophysical J. 2524-2536 (1993)
	C24	Bjorklund, 14 Trends Neurosci. 319-322 (1991)
	C25	Gruber, 54 Transplantation 1-11(1992)
	C26	Zheng et al., 88 Proc. Natl. Acad. Sci. 8067-8071 (1991)
	C27	Duncan et al, 17 J. Neurocytology 351-360 (1988)
	C28	Lundberg et al., 139 Exp. Neurol. 39-53 (1996)
	C29	Tornatore et al., 5 Cell Transplant 145-163 (1996)
	C30	Ridet et al., 10 Hum. Gene Ther. 271-280 (1999)
	C31	Faaland et al., 11 Mol. Cell Biol. 2697-2703 (1991)
	C32	Weiss et al., 16 J. Neurosci. 7599-609 (1996)
	C33	Cunningham & McKay, 47 J. Neurosci. Methods 105-14 (1993)
	C34	Brustle et al., 15 Neuron 1275-85 (1995)
	C35	Olsson et al., 79 Neuroscience 57-78 (1997)
	C36	Gates et al., 84 Neuroscience 1013-1023 (1998)
	C37	Lin, Q. et al., 8 Human Gene Therapy 331-339 (1997)
	C38	Yong, V.W. et al., 88 Proc. Nat. Aca. Sci. USA 7016-7020 (1991)
	C39	Palmer, T.D. et al., 8 Mol. and Cell. Neur. 389-404 (1997)
	C40	Eriksson, Cecilia et al., 164 Exp. Neur. 184-199 (2000)
	C41	Eriksson, C. et al., 12 Supp. 11 Eur. J. of Neur. 263 (2000)
	C42	Fagerstrom, C. et al., 12 Supp. 11 Eur. J. of Neur. 326 (2000)
	C43	International Search Report, issued March 9, 2001

RECEIVED
OCT 11 2001
TECH CENTER 1500/2900

Applicants: Wahlberg *et al.*
U.S.S.N.: 09/696,530

A copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application,
U.S.S.N. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120
(continuation, continuation-in-part, and divisional applications).



Examined Signature		Date Considered	
-----------------------	--	--------------------	--

REMARKS: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

TRA 1509131v1